Neuroprotection for glaucoma: Requirements for clinical translation
Autor: | Richard T. Libby, Leonard A. Levin, Paul A. Sieving, Alfred Sommer, Robert W. Nickells, Y. Joyce Liao, Larry A. Donoso, Harry A. Quigley, Megan E. Crowe, Richard H. Masland, M Francesca Cordeiro |
---|---|
Rok vydání: | 2017 |
Předmět: |
Retinal Ganglion Cells
Drug Intraocular pressure media_common.quotation_subject Central nervous system Glaucoma Neuroprotection Article Translational Research Biomedical 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine In vivo Optic Nerve Diseases medicine Animals Humans media_common business.industry Mechanism (biology) medicine.disease Axons Sensory Systems Ophthalmology Neuroprotective Agents medicine.anatomical_structure Retinal ganglion cell Astrocytes 030221 ophthalmology & optometry business Neuroscience 030217 neurology & neurosurgery |
Zdroj: | Experimental Eye Research. 157:34-37 |
ISSN: | 0014-4835 |
Popis: | Within the field of glaucoma research, neuroprotection is defined as slowing the functional loss in glaucoma by a mechanism independent of lowering of intraocular pressure. There is currently a great potential for research surrounding neuroprotection as it relates to glaucoma. Anatomical targets for neuroprotection should focus on upstream rather than downstream factors, and could include any part of the retinal ganglion cell, the glia, especially astrocytes or Muller cells, and vasculature. The great number of anatomical targets is exceeded only by the number of possible biochemical pathways and potential treatments. Successful treatment may be accomplished through the targeting of one or even a combination of multiple pathways. Once a treatment is shown effective in vitro, it should be evaluated in vivo with carefully chosen animal models and studied in sufficient numbers to detect statistically and clinically significant effects. Such a drug should have few systemic side effects and its delivery should be optimized so as to encourage compliance. There are still a multitude of possible screens available to test the efficacy of a neuroprotective drug and a single gold standard is ideal for the accurate assessment and comparison of new drugs. Future studies in neuroprotection should investigate the genetic component of the disease, novel pharmaceutical agents for new or known pathways, modulations of scleral biomechanics, and relation to research of other complex disorders of the central nervous system. |
Databáze: | OpenAIRE |
Externí odkaz: |